Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance

References

• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
   PubMed Web of Science ®Google Scholar
• Billmeier U, Dieterich W, Neurath MF, et al. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42):9300–9313.
   PubMed Web of Science ®Google Scholar
• Levin AD, Wildenberg ME. van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis. 2016;10(8):989–997.
   PubMed Web of Science ®Google Scholar
• Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017;14(1):22–31.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products. 2014;
   Google Scholar
• O’Callaghan J, Barry SP, Bermingham M, et al. Regulation of biosimilar medicines and current perspectives on interchangeability and policy. Eur J Clin Pharmacol. 2019;75(1):1–11.
   PubMed Web of Science ®Google Scholar
• EU Approved/positive opinion biosimilars by molecule April 2022 [Internet]. [ cited 2022 Sep 13]. Available from: https://www.biosimilars-nederland.nl/wp-content/uploads/2022_05_01-Table-EU-licensed-biosimilars-by-molecule_April_2022.pdf.
   Google Scholar
• Troein P, Newton M, Scott K. The Impact of Biosimilar Competition in Europe. IQVIA Institute for Human Data Science. 2021;33.
   Google Scholar
• Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis [Internet]. 2013;7(7):586–589.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Raine T, et al. ECCO Position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis. 2017;11(1):26–34.
   PubMed Web of Science ®Google Scholar
• European Crohn’s and Colitis Organisation. ECCO partners in Europe [Internet]. [ cited 2022 Jan 28]. Available from: https://www.ecco-ibd.eu/about-ecco/ecco-partners/category/ecco-partners-in-europe.html.
   Google Scholar
• Government of the Netherlands. EU, EEA, EFTA and Schengen countries [Internet]. 2022 [Cited 27 Jan 2022]. https://www.netherlandsworldwide.nl/eu-eea-efta-schengen-countries.
   Google Scholar
• European Medicines Agency. Remsima: EPAR - Product Information [Internet]. 2019 [Cited 2021 Nov 9]. p. 167–172. Available from: https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf.
   Google Scholar
• Sarnola K, Merikoski M, Jyrkkä J, et al. Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open. 2020;10(5):e034183.
   PubMed Web of Science ®Google Scholar
• Barbier L, Simoens S, Vulto AG, et al. European Stakeholder Learnings Regarding Biosimilars: part II - Improving Biosimilar Use in Clinical Practice. BioDrugs. 2020;34(6):797–808.
   PubMed Web of Science ®Google Scholar
• Rémuzat C, Dorey J, Cristeau O, et al. Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy. 2017;5(1):1272308.
   PubMedGoogle Scholar
• Barcina Lacosta T, Vulto AG, Huys I, et al. An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain. Front Med (Lausanne). 2023;9:1029040.
   PubMed Web of Science ®Google Scholar
• Field MK, Lohr KN. Guidelines for clinical practice: from development to use. Verh K Acad Geneeskd Belg. Washington DC: National Academic Press; 1992.
   Google Scholar
• Varma M, Almarsdóttir AB, Druedahl LC. “Biosimilar, so it looks alike, but what does it mean?” A qualitative study of Danish patients’ perceptions of biosimilars. Basic Clin Pharmacol Toxicol. 2022;130(5):1–11.
   Web of Science ®Google Scholar
• Peyrin-Biroulet L, Lönnfors S, Avedano L, et al. Changes in inflammatory bowel disease patients’ perspectives on biosimilars: a follow-up survey. United European Gastroenterol J. 2019;7(10):1345–1352.
   PubMed Web of Science ®Google Scholar
• Trystram N, Abitbol V, Tannoury J, et al. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Aliment Pharmacol Ther. 2021;53(8):887–899.
   PubMed Web of Science ®Google Scholar
• Lontai L, Gonczi L, Balogh F, et al. Non-medical switch from the originator to biosimilar and between biosimilars of Adalimumab in inflammatory bowel disease – a prospective, multicentre study. Digestive Liver Dis. 2022;54(12):1639–1645.
   Web of Science ®Google Scholar
• Mazza S, Piazza O, Sed N, et al. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): a multicenter cohort study. Clin Transl Sci. 2022;15(1):172–181.
   PubMed Web of Science ®Google Scholar
• Meijboom RW, Gardarsdottir H, Egberts TCG, et al. Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: a Systematic Review. BioDrugs. 2022;31(1):27–39.
   Google Scholar
• Boone NW, Liu L, Romberg-Camps MJ, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol. 2018;74(5):655–661.
   PubMed Web of Science ®Google Scholar
• Barbier L, Mbuaki A, Simoens S, et al. Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: a Call for Strengthened One Voice Messaging. Front Med (Lausanne). 2022;9:820755.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Godman B, Huys I, et al. The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: an Overview of Pricing and National Policy Measures. Front Pharmacol. 2021;11:1–17.
   Web of Science ®Google Scholar
• Vogler S, Schneider P, Zuba M, et al. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure. Front Pharmacol. 2021;12:1–16.
   Web of Science ®Google Scholar
• Rémuzat C, Kapuśniak A, Caban A, et al. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. J Mark Access Health Policy. 2017;5(1):1307315.
   PubMedGoogle Scholar
• European Medicines Agency. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU [Internet]. 2022 [cited 2022 Dec 19]. Available from: https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf.
   Google Scholar
• Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PLoS One. 2017;12(12):e0190147.
   PubMed Web of Science ®Google Scholar
• Jensen TB, Bartels D, Sædder EA, et al. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars. Eur J Clin Pharmacol. 2020;76(1):35–40.
   PubMed Web of Science ®Google Scholar
• Barbier L, Simoens S, Declerck P, et al. Biosimilar Use and Switching in Belgium: avenues for Integrated Policymaking. Front Pharmacol. 2022;13:821616.
   PubMed Web of Science ®Google Scholar
• Duggan B, Smith A, Barry M. Uptake of biosimilars for TNF-α inhibitors Adalimumab and etanercept following the best-value biological medicine initiative in Ireland. Int J Clin Pharm. 2021;43(5):1251–1256.
   PubMed Web of Science ®Google Scholar